Cargando…

Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases

Duvelisib (Copiktra(®)) is a dual inhibitor of phosphoinositide 3-kinases (PI3Kδ and PI3Kγ). In 2018, duvelisib was first approved by the Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodrigues, Daniel A., Sagrillo, Fernanda S., Fraga, Carlos A. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631818/ https://www.ncbi.nlm.nih.gov/pubmed/31064155 http://dx.doi.org/10.3390/ph12020069

Ejemplares similares

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
por: Mayence, Annie, et al.
Publicado: (2019)

Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases
por: Zhu, Yan, et al.
Publicado: (2022)

The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: G. de la Torre, Beatriz, et al.
Publicado: (2019)

FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis
por: Benedetto Tiz, Davide, et al.
Publicado: (2022)

Effects of 31 FDA approved small-molecule kinase inhibitors on isolated rat liver mitochondria
por: Zhang, Jun, et al.
Publicado: (2016)

A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors
por: Jin, Ying, et al.
Publicado: (2020)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies
por: Faia, Kerrie, et al.
Publicado: (2018)

Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of Plasmodium vivax Malaria and Prophylaxis of Malaria
por: Mayence, Annie, et al.
Publicado: (2019)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Obinutuzumab: A FDA approved monoclonal antibody in the treatment of untreated chronic lymphocytic leukemia
por: Sachdeva, Mamta, et al.
Publicado: (2015)

FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021
por: Sochacka-Ćwikła, Aleksandra, et al.
Publicado: (2022)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Molecular docking of monkeypox (mpox) virus proteinase with FDA approved lead molecules
por: Arasu, M.Valan, et al.
Publicado: (2023)

Use of FDA‐Approved Medications: Biologics for Psoriatic Arthritis in Patients at an Urban Outpatient Rheumatology Clinic
por: Khanna, Ira, et al.
Publicado: (2019)

Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
por: Cicenas, Jonas, et al.
Publicado: (2021)

FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders
por: Lui, Austin, et al.
Publicado: (2022)

Evaluation of Crimean-Congo hemorrhagic fever virus in vitro inhibition by chloroquine and chlorpromazine, two FDA approved molecules
por: Ferraris, O., et al.
Publicado: (2015)

The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2018)

The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2020)

The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2021)

The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2022)

The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2023)

Inhibition of HEV Replication by FDA-Approved RdRp Inhibitors
por: Hooda, Preeti, et al.
Publicado: (2023)

A Systematic Analysis of Physicochemical and ADME Properties of All Small Molecule Kinase Inhibitors Approved by US FDA from January 2001 to October 2015
por: O’Brien, Zhihong, et al.
Publicado: (2017)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Neoadjuvant therapy gains FDA approval in non-small cell lung cancer
por: Leal, Ticiana A., et al.
Publicado: (2022)

A microscopy-based small molecule screen in primary neurons reveals neuroprotective properties of the FDA-approved anti-viral drug Elvitegravir
por: Merz, Simon F., et al.
Publicado: (2020)

Inhibition of Urease by Disulfiram, an FDA-Approved Thiol Reagent Used in Humans
por: Díaz-Sánchez, Ángel Gabriel, et al.
Publicado: (2016)

Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study
por: Sankhe, Runali, et al.
Publicado: (2021)

REPURPOSING OF FDA APPROVED COMPOUNDS TO INHIBIT OSM/OSMR SIGNALING IN GLIOBLASTOMA
por: Lotfipour, Farzaneh, et al.
Publicado: (2023)

In Silico Screening and Testing of FDA-Approved Small Molecules to Block SARS-CoV-2 Entry to the Host Cell by Inhibiting Spike Protein Cleavage
por: Ozdemir, E. Sila, et al.
Publicado: (2022)

Deconvolution of bulk RNA sequencing in activated phosphoinositide 3‐kinase δ syndrome
por: Huang, Xia, et al.
Publicado: (2023)

Antitumor effects of duvelisib on Epstein–Barr virus‐associated lymphoma cells
por: Kawada, Jun‐ichi, et al.
Publicado: (2018)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l96uk5451vjtv7epleptm5l33d